Lars Fruergaard Jorgensen (L) , CEO of Danish drugmaker Novo Nordisk, maker of the blockbuster diabetes and weight-loss treatments Ozempic and Wegovy, and Chief Financial Officer Karsten Munk Knudsen (2ndL) present the annual report at Novo Nordisk in Bagsvaerd, Denmark, on February 5, 2025. Danish drugmaker Novo Nordisk, maker of the blockbuster diabetes and weight-loss treatments Ozempic and Wegovy, said on Wednesday its net profit jumped 21 percent in 2024 to 100 billion Danish kroner ($13.9 billion). Europe's most valuable company said its sales rose 25 percent to 290.4 billion Danish kroner, propelled by its popular injections. (Photo by Mads Claus Rasmussen / Ritzau Scanpix / AFP) / Denmark OUT (Photo by MADS CLAUS RASMUSSEN/Ritzau Scanpix/AFP via Getty Images)